BTIG analyst Ryan Zimmerman has reiterated their neutral stance on GMED stock, giving a Hold rating yesterday.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ryan Zimmerman has given his Hold rating due to a combination of factors impacting Globus Medical. The company recently experienced an unexpected change in management, which can create uncertainty about its strategic direction. Additionally, while the preliminary results showed a slight outperformance in Nevro sales, the base business did not meet expectations, raising concerns about its long-term stability.
Despite reaffirming its fiscal year 2025 guidance, there are questions regarding the health of Globus Medical’s legacy Spine business, which has shown signs of weakness. The company needs to achieve significant growth in the Spine segment to meet its guidance, which may be challenging in a potentially stable or slowing market. Furthermore, while the stock’s valuation has become more favorable after recent pullbacks, the overall setup for the remainder of the fiscal year appears challenging, with the need for guidance adjustments and clarity on future performance before estimates can improve.
GMED’s price has also changed dramatically for the past six months – from $92.410 to $51.890, which is a -43.85% drop .